Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer

PURPOSE: Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. MATERIALS AND METHODS: Safety data were collected prospectively and we retrospectively collected efficacy data from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatier, Renaud, Diéras, Véronique, Pivot, Xavier, Brain, Etienne, Roché, Henri, Extra, Jean-Marc, Monneur, Audrey, Provansal, Magali, Tarpin, Carole, Bertucci, François, Viens, Patrice, Zemmour, Christophe, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192912/
https://www.ncbi.nlm.nih.gov/pubmed/29281873
http://dx.doi.org/10.4143/crt.2017.446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192912/
https://www.ncbi.nlm.nih.gov/pubmed/29281873
http://dx.doi.org/10.4143/crt.2017.446

Ejemplares similares